Xanthopoulou, M.; Evangelidis, P.; Poulis, D.; Gavriilaki, E.; Kotsiou, N.; Antza, C.; Kotsis, V.; Doxani, C.; Mprotsis, T.; Zintzaras, E.;
et al. Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. Pharmaceuticals 2026, 19, 462.
https://doi.org/10.3390/ph19030462
AMA Style
Xanthopoulou M, Evangelidis P, Poulis D, Gavriilaki E, Kotsiou N, Antza C, Kotsis V, Doxani C, Mprotsis T, Zintzaras E,
et al. Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. Pharmaceuticals. 2026; 19(3):462.
https://doi.org/10.3390/ph19030462
Chicago/Turabian Style
Xanthopoulou, Maria, Paschalis Evangelidis, Dimitrios Poulis, Eleni Gavriilaki, Nikolaos Kotsiou, Christina Antza, Vasilios Kotsis, Chrysoula Doxani, Theodoros Mprotsis, Elias Zintzaras,
and et al. 2026. "Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control" Pharmaceuticals 19, no. 3: 462.
https://doi.org/10.3390/ph19030462
APA Style
Xanthopoulou, M., Evangelidis, P., Poulis, D., Gavriilaki, E., Kotsiou, N., Antza, C., Kotsis, V., Doxani, C., Mprotsis, T., Zintzaras, E., & Anyfanti, P.
(2026). Glucagon-like Peptide-1 Receptor Agonists and Platelet Function: Potential Benefits Beyond Glycemic Control. Pharmaceuticals, 19(3), 462.
https://doi.org/10.3390/ph19030462
